Nippon India Pharma Fund

Nippon India Mutual Fund · Sectoral / Thematic · Direct Growth · AMFI 118759 · ISIN INF204K01I50
NAV₹666.342020 Nov 2026
3Y return+17.96%a year
5Y return+15.40%a year
Expense ratio0.98%₹9,087 Cr
Growth Score75.2★★★★

Returns

1M3M6MYTD1Y3Y5Y7Y10YSince launch
Fund+11.40%+3.74%+8.55%+16.94%+15.26%+17.96%+15.40%+22.56%+16.61%+17.63%
NIFTY Pharma TRI+10.85%+7.49%+14.67%+25.66%+25.86%+22.31%+16.87%———
Category middle+7.06%+0.76%+8.56%+4.78%+4.51%+14.52%+13.44%+17.70%+15.67%—

Risk (36 months)

Volatility14.10%
Sharpe0.81
Sortino1.28
Beta0.89
Alpha-1.86%
Deepest fall-24.02%
1-year periods with a loss23%
5Y SIP XIRR+18.24%

Top holdings (31 Oct 2026)

Sun Pharmaceutical Industries Limited11.55%
Divi's Laboratories Limited6.73%
Cipla Limited6.21%
Lupin Limited6.16%
Dr. Reddy's Laboratories Limited6.13%
Apollo Hospitals Enterprise Limited5.10%
Mankind Pharma Limited4.40%
Sai Life Sciences Limited4.04%
Ajanta Pharma Limited3.53%
Max Healthcare Institute Limited3.31%
IPCA Laboratories Limited2.90%
GlaxoSmithKline Pharmaceuticals Limited2.83%

Sectors

Pharmaceuticals & Biotechnology75.0%
Healthcare Services21.8%
Retailing2.3%
Healthcare Equipment & Supplies0.5%

Calculated by Growth Analyser from AMFI NAVs and the fund house's disclosed portfolio. Up to 1 year: total return; longer: CAGR. Research and education only; not investment advice. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not indicate future returns.